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Summary
Background In adult asthma, bronchial hyper-responsiveness (BHR) to indirect stimuli reflects
eosinophilic activation more closely than BHR to stimuli that directly cause smooth muscle
contraction.
Aim To assess the relationship between BHR to the indirect stimulus hypertonic saline (HS), blood
eosinophil numbers, and serum eosinophilic cationic protein (ECP) in children with and without
current wheeze.
Methods A cross-sectional survey among 8–13-year-old schoolchildren, using the International
Study of Asthma and Allergic disease in Childhood questionnaire, bronchial challenge with HS, skin
prick tests, serum IgE, blood eosinophil counts and ECP (in a subset). Based upon the presence of
current wheeze (WHE) and BHR, we defined three case groups (WHE1BHR1, WHEBHR1,
WHE1BHR ) and the reference group (WHEBHR ). By regression analyses, each case group
was compared with the reference group for differences in atopic sensitization, blood eosinophil
counts and serum ECP.
Results Complete data were obtained for 470 children. BHR was present in 103 children (22%), 66
being asymptomatic and 37 symptomatic. Children of all three case groups were more often atopic.
Sensitization to indoor allergens particularly occurred in children with BHR, irrespective of
symptoms (Po0.05).
Children with WHE1BHR1 had highest values for blood eosinophils and serum ECP (Po0.05).
Children with WHEBHR1 had less severe responsiveness. In atopic children with
WHEBHR1, serum ECP was higher than in children with WHE-BHR-(Po0.05).
Conclusions BHR to HS is associated with blood markers of eosinophilic activation, particularly in
atopic children.
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Introduction
Asthma is characterized by variable airway obstruction and
bronchial hyper-responsiveness (BHR). Chronic inflamma-
tion is presumed to be the principal pathology, with remod-
elling of the airways as the final outcome. Eosinophils and
mast cells constitute the predominant cell types in the inflam-
matory process [1–4]. Mast cell mediators stimulate the release
mediators from eosinophils [5–7], and conversely eosinophilic
mediators can activate mast cells [8, 9]. This inflammatory
process is thought to contribute to the presence of airway hyper-
responsiveness, a core feature of asthma.
In epidemiological studies, BHR in children is commonly
assessed by inhalation of hypertonic saline (HS). The mech-
anism of airway constriction in response to this stimulus acts
by increasing airway osmolarity, which is presumed to cause
degranulation of mediators from mast cells such as histamine
and leukotrienes that subsequently cause bronchoconstriction
[10]. The increased number and activation state of mast cells
in asthmatic subjects explains the higher sensitivity of asth-
matics to inhaled HS. The observed relationship between
mast cells and eosinophils furthermore suggests that BHR to
HS may be a marker of eosinophilic inflammation in the
bronchi. This is supported by observations that corticosteroid
treatment reduces BHR to HS to a greater extent than BHR
to methacholine [11–13]. More directly, Gibson et al. [14] found
a dose–response relationship between the dose of HS causing
a 15% fall in FEV1 (PD15) and sputum eosinophil numbers,
whereas no such relationship was observed for BHR to
methacholine. In a general population study, BHR to HS was
also associated with a higher number of sputum eosinophils,
though only if symptoms were present as well [15]. However,
this population comprised only 156 children of whom 23
(15%) had BHR, and limited subgroup analysis.
The aim of the present study was to evaluate eosinophilic
activation, assessed by blood eosinophil counting and serum
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eosinophilic cationic proterin (ECP), in BHR to HS. We
hypothesized that such a relationship would be independent
of the presence of wheeze in the past 12 months.
Methods
Study population and design
The population comprised 2207 Dutch schoolchildren, aged
8–13 years, who participated in a cross-sectional study on
respiratory health effects of living close to freeways. Respir-
atory health was assessed using International Study of Asthma
and Allergic disease in Childhood (ISAAC) phase 2 standards,
including questionnaire data on asthma symptoms (N5
2159), skin prick tests (SPTs) (N5 1350) and bronchial chal-
lenge test with HS (N5 1258) [16]. In addition, we included
blood withdrawal (N5 1073) for eosinophil counting (N5
1030), and IgE analyses (N5 1036). In 521 children serum
eosinophilic cationic protein (ECP) was assessed by a 1 : 2
nested case–control sample in which individuals with an
affirmative answer on ‘ever asthma’, ‘wheeze in the past 12
months’ or ‘dry cough without a cold in the past 12 months’,
were considered cases.
The Medical Ethical Board of the University of Wagenin-
gen approved the study and written informed consent was
obtained for each child from a parent or legal locum. Parents
had to give permission for each test separately, which explains
the difference in participation for the various parts of the
study. The final study population for this analysis constituted
of 470 children who participated in all tests.
Questionnaire
In addition to the ISAAC questionnaire, we collected data on
socio-demographic characteristics, housing conditions, med-
ical treatment, family history of asthma, and environmental
tobacco smoke (ETS).
Atopic status
Atopy was assessed by SPT and serum-specific IgE. SPTs
were performed according to the ISAAC phase 2 standards to
a panel of seven common allergens (ALK-Abello, Horsholm,
Denmark). Serum-specific IgE was assessed by the CAP-assay
(Pharmacia, Woerden, the Netherlands). The Phadiatop was
used as a screening instrument for allergy to common
inhalant allergens [17]. Sera with a positive result were tested
for specific IgE. Allergens tested in SPTs and/or IgE analysis
comprised: (1) mixed grass pollen (Anthoxanthum odoratum,
Avena eliator, Dactylis glomerata, Festuca pratensis, Holcus
lanatus, Lolium perennae, Phleum pratense, Poa pratensis,
Secale cereale), (2) mixed tree pollen (Alnus glutinosa, Betula
verrucosa, Corylus avellana, Quercus alba, Salix caprea), (3)
cat dander, (4) dog dander, house dust mites (HDMs), (5)
Dermatophagoides farinae, (6) D. pteronyssinus, and (7)
moulds (Alternaria tenuis, Cladosporium herbarum, Penicilli-
num notatum).
A positive SPT was defined if the mean weal diameter
X3mm, and if result on specific IgE as a titre ofX0.35 kU/L
is positive. Children with either a positive result by SPT or by
specific IgE were considered atopic. We distinguished indoor
allergens as HDM, cat and dog dander, and outdoor allergens
as moulds, grass and tree pollen.
Serum ECP
Serum ECP was determined by fluoro-immunoassay (Phar-
macia) by the same lab that performed IgE analyses (Phar-
macia). Blood and serum handling occurred according to the
test manufacturer’s protocol.
Blood eosinophils
Blood eosinophils were determined by Coulter counter auto-
analyser and expressed as the number of cells per litre (AML,
Anvers, Belgium).
Lung function and bronchial challenge
Prior to the bronchial challenge test, lung function was deter-
mined using a pneumotachometer (Jaeger, Wu¨rzburg, Germany)
according to guidelines of the ERS [18]. Salbutamol was stopped
6h before the bronchial challenge test, antihistaminics and
cromoglycate 48h. Children were excluded from bronchial
challenge if the forced expiratory volume in 1 s (FEV1) was
below 75% of the predicted value (N50), or if they were unable
to perform acceptable forced spirometry manoeuvre at baseline
(N517). Data of another 12 children were excluded because
they were unable to complete the test because of excessive cough.
Briefly, an aerosol of 4.5% saline was inhaled for 0.5, 1, 2, 4
and 8min, and two reproducible measurements of FEV1 were
achieved 1min after each inhalation step of which the higher
was selected. The test stopped after completing all inhalation
steps, or if there was a fall in FEV1X15% compared with the
highest pre-challenge FEV1. PD15 HS was assessed by linear
interpolation and BHR was defined as a PD15 HS 423mL,
which has shown similar sensitivity and specificity for asthma
symptoms and diagnosis as BHR to histamine [19]. To
include a measure of bronchial responsiveness for each child,
including those without BHR, we calculated the dose–
response slope (DRS) as the maximum % fall in FEV1 per
inhaled millitre of HS [20, 21].
Statistical analysis
Logistic regression analysis was performed to select respira-
tory symptoms that were independently associated with
BHR. To this, we evaluated symptoms in the past 12 months
of wheeze, a dry cough, chronic phlegm, and a doctor’s
diagnosed bronchitis. In bivariate analyses current wheeze
and a dry cough were associated with BHR (odds ratio
(OR)wheeze5 3.46, 95% CI 2.48; 4.83, and ORcough5 1.77,
95% CI 1.27; 2.46). In multivariate analyses with both
symptoms in the model, statistical significance was only
present for wheeze (OR 3.43, 95% CI 2.39; 4.91). Therefore,
we defined outcomes on asthma symptoms and BHR by the
presence of wheeze in the past 12 months as
WHE1BHR1 ‘Wheeze in the past 12 months’ and BHR
WHEBHR1 No ‘wheeze in the past 12 months’ and BHR
WHE1BHR ‘Wheeze in the past 12 months’ and no BHR
WHEBHRNo ‘wheeze in the past 12 months’
and no BHR
WHE, wheeze; BHR, bronchial hyper-responsiveness.
BHR to hypertonic saline and blood eosinophilic markers 1227
r 2004 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 34:1226–1231
For each case group (WHE1BHR1, WHEBHR1,
WHE1BHR ), the differences in atopy, blood eosinophils,
serum ECP, and DRS were assessed using children without
wheeze and no BHR (WHEBHR ) as reference group.
Regression analysis was performed in order to adjust for
potential confounders: logistic regression for atopic sensitiza-
tion, and linear regression for continuous variables (DRS,
blood eosinophils, serum ECP). Prior to linear regression,
variables were log transformed to normalize the distributions.
The results were expressed as ORs for logistic regression, and
percentage difference compared with the reference for linear
regression. Since eosinophils and ECP are associated with
atopy irrespective of the presence of asthma, we repeated the
analyses for atopics only.
All statistical analyses were performed using the SAS 8.02
statistical software package.
Results
The study population comprised 470 children who completed
all tests. Table 1 shows characteristics of participants and
non-participants. Participants were older, more often boys,
and more often atopic. The prevalence of wheeze, BHR, and
a parental history of atopy were similar in participants and
non-participants.
As shown in Table 2, BHR was present in 103 children, 37
(36%) symptomatic. These 37 children comprised 43% of the
86 children with recent wheeze. In children with BHR, the
degree of responsiveness was higher if symptoms were present
as well, irrespective whether expressed as DRS or PD15. In
children without BHR, the DRS was similar in children with
and without symptoms.
Atopy occurred more often in children with BHR and/or
symptoms compared with children without symptoms and no
BHR (WHEBHR ). The higher sensitization rate was
most pronounced for indoor allergens. Particularly HDM
sensitization occurred more frequently in all three outcomes
with wheeze or BHR compared with children without wheeze
and no BHR (Po0.05). Considering other allergens, children
with WHE1BHR1 consistently had highest sensitization
rates (all Po0.05 compared with WHEBHR ). Adjust-
ment for potential confounders by logistic regression analyses
yielded similar results (Table 3), except for a loss of statistical
significance for sensitization to indoor allergens in children
classified as WHE1BHR . Lack of statistical power due to
small numbers limited more detailed analyses on the con-
tribution of individual allergens.
Figure 1 shows the results of multiple regression analyses
for blood eosinophils and serum ECP. Blood eosinophils and
serum ECP were higher in children with symptomatic BHR
(Fig. 1a). Considering atopic children only (Fig. 1b),
differences with the reference group of WHEBHR
became more pronounced. Again blood eosinophils and
serum ECP were highest in children with symptomatic BHR
(Po0.05). In addition, atopic children with asymptomatic
BHR had a higher level of serum ECP (Po0.05). DRS and
PD15 were similar in atopic and non-atopic children with
asymptomatic BHR.
In the analyses above, we used wheeze in the past 12
months as discriminatory symptom since it was the only
symptom associated with BHR in logistic regression analyses
that included other respiratory symptoms as well. Bias might
occur if other asthma symptoms are present in children
categorized as asymptomatic. For ‘a dry cough at night in the
past 12 months’, this occurred in 21% and 42% of the
children with WHEBHR1 and WHEBHR , respec-
tively. Exclusion of these children did not change the results.
Corticosteroid treatment is known to reduce asthma
symptoms and eosinophilic inflammation and might therefore
affect the results. In this population, inhaled corticosteroid
Table 1. Characteristics of participants and non-participants
Participants
(N5 470)
Non-participants
(N5 1737)
Age, mean (range) 10.4 (8–13) 9.6 (8–13)*
Girls 46 52**
Atopy 37 31**
Wheeze in the past 12 months 18 17
Ever asthma 10 8
Inhaled corticosteroid treatment 4 3
FEV1, mean %-predicted (range) 100 (75–130) 101 (55–186)
BHR 22 21
*Po0.01, **Po0.05, for difference between participants and non-participants.
BHR, bronchial hyper-responsiveness; FEV1, forced expiratory volume in 1 s.
Table 2. Atopic sensitization, pre-challenge lung function, DRS, PD15, blood eosinophils, and serum ECP by outcome defined by the presence of wheeze
and BHR
WHE1BHR1
(N5 37)
WHEBHR1
(N5 66)
WHE1BHR
(N5 49)
WHEBHR
(N5 318)
Atopic sensitization (%)
Any allergen 81* 44** 47** 29
Indoor allergensw 81* 38** 39** 23
Outdoor allergensz 60* 26 31 19
FEV1 (% predicted)§ 97 (94, 101) 100 (97, 102) 102 (99, 105) 101 (100, 102)
DRS (% per mL)z 2.6 (1.9, 3.4)* 1.5 (1.3, 1.8)* 0.2 (0.1, 0.3) 0.2 (0.1, 0.2)
PD15 (mL)z 5.8 (4.3, 7.6)*** 9.6 (8.0, 11.4) Not assessed Not assessed
Blood eosinophils (  106/mL)z 347 (269, 446)* 200 (156, 255) 224 (179, 281) 209 (14, 225)
Serum ECP (mg/mL)z 10.2 (7.2, 14.5)* 6.8 (5.5, 8.3) 7.1 (5.5, 9.2) 6.2 (5.6, 6.8)
*Po0.01, **Po0.05, compared with WHEBHR , ***Po0.01 compared with WHEBHR1. wMoulds, grass or tree pollen. zCat, dog, or HDM (see Methods
section). §According to Zapletal et al. [22], mean (95% CI). zGeometric mean (95% CI).
DRS, dose–response slope; ECP, eosinophilic cationic protein; BHR, bronchial hyper-responsiveness; WHE, wheeze; FEV1, forced expiratory volume in 1 s.
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treatment was used in 32% of the children with
WHE1BHR1, in 16% with wheeze WHE1BHR and
none of the children with WHE1BHR or WHEBHR .
Exclusion of children using corticosteroid treatment did not
change the results essentially.
Discussion
In this study among 8–13-year-old schoolchildren, BHR to
HS was associated with atopy, particularly to indoor aller-
gens. These associations were independent of the presence of
recent wheeze. Children with symptomatic BHR had a higher
blood eosinophil number and serum ECP than those without
symptoms and/or BHR. In atopic children, serum ECP was
also higher in children with asymptomatic BHR compared
with children without symptoms and no BHR.
We have made an attempt to estimate the relationship
between BHR to HS and eosinophilic inflammation in a
general population of schoolchildren. It has been previously
shown in atopic asthma that BHR to an indirect stimulus is
related to the underlying eosinophilic inflammation, as
Table 3. ORs and 95% CI for atopic sensitization defined by the presence of wheeze and BHR
Reference: WHEBHR
WHE1BHR1 WHEBHR1 WHE1BHR
OR (95% CI)* OR (95% CI)* OR (95% CI)*
Atopy
Any allergen 11.25 (4.38, 28.92)** 2.36 (1.24, 4.50)*** 2.11 (1.04, 4.27)z
Indoor allergensw 12.39 (4.21, 36.50)** 2.34 (1.07, 5.12)*** 1.66 (0.69, 3.99)
Outdoor allergens 1.68 (0.65, 4.38) 1.06 (0.46, 2.48) 1.38 (0.56, 3.41)
Number of sensitizations
Any allergen 2.08 (1.67, 2.59)** 1.25 (1.01, 1.54)*** 1.24 (0.99, 1.54)
Indoor allergens 5.49 (3.10, 9.73)** 1.54 (1.00, 2.37) 1.51 (0.97, 2.36)
Outdoor allergens 0.54 (0.24, 1.23) 1.00 (0.56, 1.77) 0.96 (0.51, 1.84)
*Adjusted for age, sex, parental history of asthma or rhinitis, parents’ birth country, parental education, current parental smoking, and parent who completed the
questionnaire. wIncluding both atopic sensitization to indoor and outdoor allergens in the model. **Po0.01, ***Po0.05 compared with WHEBHR .
BHR, bronchial hyper-responsiveness; WHE, wheeze; OR, odds ratio; 95% CI, 95% confidence interval.
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Fig. 1.Blood eosinophils and serum eosinophilic cationic protein (ECP) for different combinations of wheeze (WHE) and bronchial hyper-responsiveness
(BHR) in the whole study population (a) and for atopic children (b) separately.
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assessed in sputum and blood [23]. However, it is largely
unknown if such a relationship is present in a general popu-
lation in which most children do not have a diagnosis of asth-
ma. It is further unknown if eosinophilic inflammation is present
in individuals with asymptomatic BHR as well.
Like others, we have found a higher prevalence rate of
atopic sensitization in children with BHR, irrespective of the
presence of wheeze [24, 25]. Sensitization only involved
indoor allergens, and particularly to HDM. In fact, children
with symptomatic BHR had the highest sensitization number
and rate. Furthermore, bronchial responsiveness was highest
in these children. Presumably, children with multiple sensi-
tizations have more severe bronchial inflammation. This may
be explained by a greater likelihood to encounter multiple
allergens (in frequency and number) that enhance bronchial
inflammation.
In this study, we used blood eosinophil counts and serum
ECP as proxy markers of eosinophilic activation. Both were
increased in symptomatic BHR, but not in asymptomatic
BHR. One may argue that blood eosinophilic markers do not
properly reflect the action in the airways. Nevertheless, van
den Berge et al. [23] found a positive correlation between
blood eosinophils and AMP responsiveness, a marker of air-
way inflammation. However, this study only included subjects
with an asthma diagnosis and BHR to methacholine (PC204
8mg/mL). In a general population study, Jo˜gi et al. [26] found
higher serum ECP levels in subjects with atopy or BHR, but
no distinction was made between symptomatic and asympto-
matic subjects. Gibson et al. [15] observed a higher number of
eosinophils in sputum of children with BHR, although only if
recent symptoms were also present.
In our population, we found similar results for blood
eosinophils. However, interpretation of these similarities needs
great cautiousness, since correlation between airway and blood
eosinophilia is poor [27, 28]. In our study, we additionally
observed more severe bronchial responsiveness in children
with symptomatic BHR compared with those with asympto-
matic BHR. Taken together, our observations suggest that
eosinophilic inflammation particularly plays a role in more
severe BHR that is more often accompanied by symptoms.
In the subgroup of atopic children, we observed higher
levels of serum ECP in children with BHR both with and
without the presence of wheeze. In contrast, blood eosino-
phils were only elevated if children had also been wheezing in
the past 12 months. The interpretation of this observation is
not fully clear. It may signify that activated blood eosinophils
are a marker of atopy, whereas increased numbers of blood
eosinophils per se more closely reflect ongoing airway
inflammation with BHR and symptoms. Alternatively, the
increased peripheral blood eosinophil counts and the possible
enhanced eosinophil activation may account for the higher
serum ECP. So far, only few studies have evaluated the
relationship between serum ECP and asthma or BHR in a
general population. Our results are consistent with clinical
studies and suggest that BHR and asthma do not allow a
description in a single inflammatory parameter [29]. This may
be considered a confirmation of the complexity and hetero-
geneity of BHR and asthma.
A relevant source of bias in our study may have been the
period reflected by either symptoms or blood eosinophilic
markers. While symptoms dated a period of the past 12
months, eosinophilic markers likely reflect an inflammatory
process that is represented over a much shorter period in
time. This may well have underestimated the relationships
between symptomatic BHR and blood eosinophilic markers.
Like others, we observed a relative high proportion of chil-
dren with asymptomatic BHR (64%) [30–33]. In this study,
we only considered a history of current wheeze as symptom
indicative for asthma. This was confirmed by multiple logis-
tic regression analyses, in which only this symptom was
independently associated with the presence of BHR. More-
over, in children without wheeze, we observed twice as much
dry cough in children without BHR (42%) compared with
those with BHR (21%). Others have shown an overlap be-
tween wheeze and chronic cough, though wheeze is the
strongest predictor for future wheeze or asthma [34, 35].
Corticosteroid treatment was neither an explanation for the
high frequency of asymptomatic BHR, since none of these
children used corticosteroids. We assume that underreporting
of symptoms is the most likely explanation. This may par-
ticularly have occurred in children with less severe symptoms,
or a larger time interval between symptoms. This is confirmed
by our observation of a milder degree of BHR in asympto-
matic BHR compared with symptomatic BHR. So far it is
unclear if asymptomatic and symptomatic BHR should be con-
sidered separate conditions or reflect different grades of
similar pathology. If the latter is the case, this may have im-
plications for the development of symptoms in the future. A
number of studies have shown an increased risk of developing
asthma in subjects with asymptomatic BHR [36–38]. So far it
is not clear which factors contribute to the development of
symptoms. Nevertheless, subjects with asymptomatic BHR
may be a relevant target group for prevention measures,
though difficult to trace in the population.
In summary, children with BHR to HS were more
frequently atopic to indoor allergens. If symptoms were
present as well, they more often had multiple sensitizations,
and higher levels of blood eosinophils and serum ECP
compared with children without BHR and no symptoms. In
atopic children, serum ECP was also higher in children with
asymptomatic BHR. Furthermore, the degree of bronchial
responsiveness was higher in symptomatic BHR compared
with asymptomatic BHR. Taken together, our results suggest
a relationship between eosinophilic inflammation, assessed by
blood eosinophils and serum ECP and the degree of bronchial
responsiveness to HS, which was present in atopic but not in
non-atopic children.
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